Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.57 |
| ▸ | HTR3A | P46098 | 1/20 | 0.51 |
| ▸ | AGXT | P21549 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1372927 | 0.81 | KCNH2 (0.69) | ADRA2CHTR3AAGXTDRD2KCNH2 | |
| SCHEMBL3597710 | 0.81 | MAPT (0.53) | ADRA2CHTR3ADRD2MAPTNPC1 | |
| SCHEMBL2599616 | 0.78 | ADRA2C (0.59) | ADRA2CHTR3AAGXTDRD2KCNH2 | |
| SCHEMBL25492995 | 0.77 | ADRA2C (0.57) | ADRA2CHTR3AAGXTDRD2KCNH2 | |
| SCHEMBL12251546 | 0.77 | ADRA2C (0.57) | ADRA2CHTR3AAGXTDRD2KCNH2 | |
| SCHEMBL3584889 | 0.76 | ADRA2C (0.61) | ADRA2CHTR3AAGXTMAPTNPC1 | |
| SCHEMBL12968842 | 0.75 | ADRA2C (0.56) | ADRA2CHTR3AAGXTDRD2KCNH2 | |
| SCHEMBL23657330 | 0.75 | KCNH2 (0.61) | ADRA2CDRD2KCNH2MAPTNPC1 | |
| SCHEMBL27818699 | 0.75 | ADRA2C (0.56) | ADRA2CHTR3AAGXTDRD2KCNH2 | |
| SCHEMBL26423291 | 0.75 | ADRA2C (0.65) | ADRA2CHTR3AAGXTKCNH2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | ADRA2C 3317/4885HTR3A 3666/4885AGXT 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.